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366 Letters to the Editormonoterpene toxic to TA100 strain in the preliminary toxicity
test. No mutagenic effect was found with () camphor, citral,
citronellal, 1,8-cineole, and ()-menthol. Terpineol caused a
slight but dose-related increase in the number of his+ rever-
tants with TA102 tester strain both without and with addition
of S9 mixture. The results from this study therefore suggest
that, with the exception of terpineol, the monoterpenoid
compounds tested are not mutagenic in the Ames test’’. Thus
not all the essential oil compounds are mutagenic.
The antifungal activity of the essential oils of Thymus on
Candida spp has been described as warranting future ther-
apeutic trials on mucocutaneous candidosis (Pina-Vaz
et al.1). Paster and co-workers2 applied essential oils from
thyme for 24 hours against the mycelia and spores of Asper-
gillus flavus, Aspergillus niger, and Aspergillus ochraceus, as
well as against the natural microflora of wheat grains. The
thyme essential oil was less efficient in controlling mycelia
and growth was observed even following exposure to 4.0 mU/
l. However, the thyme essential oil was fungitoxic to spores
(MIC = 3.0 mU/l). In another set of trials the efficacy of the
oils and two of their constituents (carvacrol and thymol) in
controlling the natural microflora of surface-sterilized wheat
grain was studied. Juliano et al.3 demonstrated that thyme
oils possessed microbicidal activities, especially against
Gram-positive bacteria (MIC range 0.125—0.500 mg/ml)
and fungi (MIC 0.125—0.500 mg/ml). Soliman and Badeaa4
reported complete inhibition of Aspergillus flavus, Aspergil-
lus parasiticus, and Aspergillus ochraceus by the oils of
thyme and cinnamon (<500 ppm), marigold (<2000 ppm),
spearmint, basil, and quyssum (3000 ppm). There is a strong
correlation between the contents of camphor, thujones and
camphene, and the oils’ toxicity. The spring extract was the
least toxic (LD50: 1200 mg/kg body weight) and contained
lower levels of camphor (7.7%), a,b-thujone (1.3%), and
camphene (3.1%). Thus, we recommend that oil extracts
of sagemarketed for use in certain unconventional medicines
be prepared from spring plants (Farhat et al.5). Owing to
strong antibacterial and excellent protective features exhib-
ited in antioxidant activity tests, the essential oil andextracts from the herbal parts of Thymus eigii were sug-
gested for consideration as a natural source that can be freely
used in the food industry as a culinary herb (Tepe et al.6).
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doi:10.1016/j.ijid.2006.08.004Cryptococcal meningitis with raised intracra-
nial pressuremasquerading asmalignant hyper-
tension
A 39-year old man had recently been diagnosed with hyper-
tension and was taking nifedipine SR. He presented with neck
pain and diffuse headache of one week’s duration, and had
blurred vision for two days; he was afebrile. His blood
pressure (BP) was 189/118 mmHg and retinal flame-shaped
hemorrhages were seen without other abnormalities. An
electrocardiogram and plain computerized tomography brain
scan were normal. His blood pressure was controlled and the
headache improved with hypotensive agents. Routine blood
tests and screening for causes of secondary hypertension
were normal or negative.
Three weeks later he developed confusion and diplopia.
Examination revealed nuchal rigidity with Glasgow comascale 13 (M5E4V4), impaired abduction of both eyes, slug-
gish left pupil, papilloedema, and flame-shaped hemor-
rhages. His BP was 199/118 mmHg. A magnetic resonance
imaging brain scan with gadolinium was normal. Lumbar
puncture showed an opening pressure of 52 cmH2O. Cere-
brospinal fluid (CSF) protein was 2.3 g/l, glucose was
2.2 mmol/l (blood 6.8), and cell count was 87  106/l
(88% lymphocytes); the CSF was positive for Cryptococcus
neoformans on microscopy with elevated cryptococcal
antigen (1:32). Amphotericin and flucytosine were started
and ventriculostomy performed for continuous intracranial
pressure (ICP) monitoring. The lowering of his BP to 138/
90 mmHg with nifedipine SR was followed by deteriorated
consciousness and confusion, which improved when his BP
surged up again. Transcranial Doppler performed during
normal BP revealed reduced flow velocities over the major
intracranial arteries, which rose to normal when his BP
surged up to 185/103 mmHg. His mental state, ICP, and BP
Letters to the Editor 367improved subsequently with full recovery. Amphotericin
and flucytosine were stopped after two weeks and were
followed by oral fluconazole for six months. He was HIV
negative. Lymphocyte subsets count and lymphocyte pro-
liferation assay were normal. He had no relapse for five
years.
Cryptococcosis is an important diagnosis for immuno-
compromised subjects,1,2 and is increasingly recognized in
the immunocompetent host.3,4 Meningitis is common in
cryptococcosis.2,5—8 Our patient had cryptococcal meningi-
tis presenting with neck pain and headache with raised ICP.
The raised ICP aggravated his hypertension via the Cushing
reflex. During the Cushing reflex, the systemic arterial
blood pressure rises in response to central nervous system
(CNS) ischemia caused by an ICP that is equal or higher than
the arterial pressure. Without end-organ damage, we
believed that his papilloedema was due to raised ICP
instead of malignant hypertension. CNS infection was not
considered initially due to the lack of fever and the pre-
sumptive diagnosis of headache due to uncontrolled hyper-
tension. The clue for CNS infection on initial presentation
was the neck pain. He deteriorated later with encephalo-
pathy, nuchal rigidity, and severe intracranial hypertension
causing papilloedema and sixth nerves compression. Upon
incidental normalization of his BP, his level of consciousness
deteriorated, which improved as his BP surged up, reflect-
ing that when cerebral autoregulation is impaired due to
meningitis, a high systemic BP is required to maintain
adequate cerebral blood flow during intracranial hyperten-
sion. This was documented objectively by the transcranial
Doppler findings.
Raised ICP causing reactive hypertension without fever or
signs of meningism can be the presenting feature of crypto-
coccal meningitis in an immunocompetent host. Clinicians
should consider CNS infection causing raised ICP when hyper-
tension and papilloedema are present without evidence of
end-organ damage to suggest malignant hypertension.
Prompt initiation of anti-fungal therapies is critical for this
potentially fatal meningitis.
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doi:10.1016/j.ijid.2006.07.005The use of ELISA in a seroprevalence study of
Brucella antibodies in West Bank Palestinian
women of childbearing age
Brucellosis is considered to be endemic in the Mediterra-
nean basin and the Middle East;1,2 Brucella melitensis is
the only Brucella species currently known to cause disease
in Israel and the Palestinian Authority.3 While human
incidence statistics from Israel and the Palestinian Author-
ity support endemicity,4,5 this has not previously been
verified by seroprevalence studies. We report a prevalence
study of Brucella antibodies in a West Bank Palestinian
population.
Cord blood was taken at delivery, after informed consent,
from 2638 Palestinian women who gave birth between 31
August 1994 and 31 March 1995 in six West Bank governmenthospitals. Of 1021 samples selected by systemic sampling,
802 were adequate for processing. All were tested by ELISA
for IgG-class Brucella antibodies (Clark). Every sixth sample,
and all ELISA-positive samples with sufficient serum (32/35
positive samples), were tested by Rose-Bengal (Sanofi) and
agglutination (SAT; Murex) tests.
Of the samples, 35/802 (4.4%) were positive by ELISA.
Nine of 32 (28.1%) ELISA-positive samples had SAT titers
1:50; one (1:400 titer) was positive by Rose-Bengal test.
All ELISA-negative samples were SAT-negative. ELISA preva-
lence varied from 3% in the summer to 7—10% in early spring
(Figure 1). Neither this nor variation by age (from 2.5% for
ages 20—24 years to 7% in the>30 years age group) or hospital
(1.3—6%) was statistically significant.
ELISA detects Brucella IgG antibodies reflecting both past
seroconversion and current disease.2,6,7 ELISA tests combine
high specificity and sensitivity and a relatively low unit
